CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Brazilian Green Propolis Extract (EPP-AF)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2846 Telehealth CBT Wiki 1.00
drug2692 Standard care Wiki 0.35

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D001008 Anxiety Disorders NIH 0.15

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.

The COVID-19 pandemic is of grave concern due its impact on human health and on the economy. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, anti-oxidant properties, and various aspects of the SARS-CoV-2 infection mechanism are potential targets for propolis compounds. Propolis components have inhibitory effects on the ACE2, TMPRSS2 and PAK1 signaling pathways; in addition, antiviral activity has been proven in vitro and in vivo. This is a pilot randomized study that aims to assess the impact of using Brazilian green propolis extract against the deleterious effects of the new coronavirus.

NCT04480593 Covid19 Drug: Brazilian Green Propolis Extract (EPP-AF) Other: Standard care

Primary Outcomes

Description: Composite clinical outcome with oxygen therapy dependency time (in days) or hospitalization time (in days) after randomization.

Measure: Composite clinical outcome with oxygen therapy dependency time or hospitalization time

Time: 1-28 days

Secondary Outcomes

Description: We will evaluate the presence or absence of symptoms related to the use of propolis through a questionnaire.

Measure: Percentage of participants with adverse events during the use of propolis

Time: 1-28 days

Description: Assess the degree of acute kidney injury according to KDIGO (through serum creatinine or urine output).

Measure: Rate and severity of acute kidney injury during the study

Time: 1-28 days

Description: Assess need or not for renal replacement therapy.

Measure: Renal replacement therapy.

Time: 1-28 days

Description: Describe the time needed for vasopressors in days after randomization

Measure: Rate of need for vasopressor use

Time: 1-28 days

Description: Assess length of stay in the ICU after randomization in days

Measure: Need for intensive care unit (ICU)

Time: 1-28 days

Description: Rate of readmission to the ICU after randomization

Measure: Intensive care unit (ICU) readmission

Time: 1-28 days

Description: Assess the need for mechanical ventilation in days after randomization.

Measure: Invasive oxygenation time

Time: 1-28 days

Description: Evaluate the variation in serum levels of c-reactive protein over the 7 days after randomization

Measure: Variation of plasma c-reactive protein

Time: 1-7 days


No related HPO nodes (Using clinical trials)